Band 2
Provided by Yi Wang
Mr. Wang Yi is a partner of Jun He Law Offices and he is the head of capital market department.
Mr. Wang has been practicing for more than 20 years with leading PRC firms and international firms in Beijing, Hong Kong and Shanghai. He is experienced in various kinds of restructuring as well as domestic and overseas listings, bond and stock issuance, mergers and acquisitions of listed companies, private equity funds investments, etc.
Mr. Wang has been recommended as an "Outstanding Lawyer" by Chambers Global Guide for many consecutive years, has been selected as “Distinguished practitioner” by asialaw for many times, and has been awarded “Other key lawyers” and “Practice head” in The Legal 500 Asia-Pacific in recent years.
Admitted to practice law in China.
Provided by Chambers
Wang Yi has extensive experience handling domestic and overseas listings as well as bond issuances. He chairs the capital markets department at JunHe.
王毅律师在处理国内和海外上市及债券发行方面经验丰富。他是君合的资本市场部的负责人。
Provided by Chambers
Wang Yi and his team always deliver innovative thoughts and solve legal questions with a business mindset.
王毅律师和他的团队总是提供创新思维，并以商业思维解决法律问题。
Wang Yi and his team always deliver innovative thoughts and solve legal questions with a business mindset.
王毅律师和他的团队总是提供创新思维，并以商业思维解决法律问题。
6 items provided by JunHe LLP
13 JunHe Deals Named as “Deals of the Year 2023” by China Business Law Journal
On March 19, 2024, China Business Law Journal unveiled their “Deals of the Year 2023” and JunHe was recognized for 13 deals.
JunHe Advises BIBO on its RMB 200 Million A+ Round Financing
JunHe assisted Bebest (Shanghai) Automotive Electronics in closing its A+ round financing, jointly led by Meridian Capital and Orinno Capital, with other investors including Fengfan Ventures, etc.
JunHe Assists Marketingforce, a SaaS Intelligent Marketing Platform, in its Listing on the HKSE
Marketingforce (02556.HK) listed on the HKSE on May 16, 2024, with shares rising 18.46% to HK$59.6, giving it a market cap of over HK$14 billion. It's among the first VIE firms to IPO in Hong Kong under new listing rules.
JunHe assists Legend Capital and Atour in completing a secondary offering of ADS
On June 13, 2024, Legend Capital completed a secondary offering of 10 million ADSs in Atour Lifestyle Holdings Limited (ATAT) at $16.90 per share, raising around $194 million.
JunHe Assists Advent International in its Investment in Seek Pet
Advent International recently completed an equity investment in Seek Pet Co., Ltd. (“Seek”), a leading Chinese pet food manufacturer.
JunHe Advises TYK Medicines’ HKEX IPO
On August 20, 2024, TYK Medicines, Inc. successfully launched its IPO and listing on the Main Board of the Hong Kong Stock Exchange under stock code 2410.HK. The offering raised approximately HK$ 579 million.
13 JunHe Deals Named as “Deals of the Year 2023” by China Business Law Journal
On March 19, 2024, China Business Law Journal unveiled their “Deals of the Year 2023” and JunHe was recognized for 13 deals.
JunHe Advises BIBO on its RMB 200 Million A+ Round Financing
JunHe assisted Bebest (Shanghai) Automotive Electronics in closing its A+ round financing, jointly led by Meridian Capital and Orinno Capital, with other investors including Fengfan Ventures, etc.
JunHe Assists Marketingforce, a SaaS Intelligent Marketing Platform, in its Listing on the HKSE
Marketingforce (02556.HK) listed on the HKSE on May 16, 2024, with shares rising 18.46% to HK$59.6, giving it a market cap of over HK$14 billion. It's among the first VIE firms to IPO in Hong Kong under new listing rules.
JunHe assists Legend Capital and Atour in completing a secondary offering of ADS
On June 13, 2024, Legend Capital completed a secondary offering of 10 million ADSs in Atour Lifestyle Holdings Limited (ATAT) at $16.90 per share, raising around $194 million.
JunHe Assists Advent International in its Investment in Seek Pet
Advent International recently completed an equity investment in Seek Pet Co., Ltd. (“Seek”), a leading Chinese pet food manufacturer.
JunHe Advises TYK Medicines’ HKEX IPO
On August 20, 2024, TYK Medicines, Inc. successfully launched its IPO and listing on the Main Board of the Hong Kong Stock Exchange under stock code 2410.HK. The offering raised approximately HK$ 579 million.
